Alpha-9 Oncology Starts Dosing First Patient in Phase 1 Trial of A9-3202 for Advanced Melanoma

Alpha-9 Oncology, a clinical-stage company devoted to the development of radiopharmaceuticals for cancer treatment globally, announced a significant milestone on May 2, 2024. The company reported the administration of an initial dose to a participant in its Phase 1 study of 68Ga-A9-3202. This radiodiagnostic agent targets the melanocortin 1 receptor (MC1R), which is used for imaging in locally advanced or metastatic melanoma. Elevated expression of MC1R is common in malignant melanoma and other skin cancers.

The ongoing Phase 1 multi-center study focuses on assessing tumour uptake and the distribution of 68Ga-A9-3202 in patients with advanced or metastatic melanoma (ACTRN12624000085572). This innovative agent is designed to work alongside traditional CT or PET/CT imaging techniques to identify suitable candidates for a novel radiotherapeutic agent targeting MC1R, also developed by Alpha-9.

Dr. Ovid Trifan, Chief Medical Officer at Alpha-9, expressed his enthusiasm about the progress, stating, "This agent is the first step in our effort to develop radiopharmaceuticals targeting MC1R for the treatment of patients with advanced or metastatic melanoma. We're excited to advance our portfolio of molecules further into the clinic."

Alpha-9 Oncology specializes in creating unique and highly targeted radiopharmaceuticals aimed at significantly enhancing cancer treatment outcomes. Utilizing proprietary technologies and profound expertise, the company is at the forefront of designing radiopharmaceuticals that deliver radiation specifically to tumor sites while minimizing off-target impacts. Alpha-9 is developing a diverse range of novel radiopharmaceuticals with a systematic approach to molecule design, presenting extensive potential for targeting various validated oncology markers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!